COGT Cogent Biosciences, Inc. Stock Quote

COGT [NASD]

Index	-	P/E	-	EPS (ttm)	-12.41	Insider Own	0.56%	Shs Outstand	34.88M	Perf Week	-7.41%
Market Cap	239.70M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-7.40%	Shs Float	33.94M	Perf Month	-26.02%
Income	-184.80M	PEG	-	EPS next Q	-0.36	Inst Own	95.63%	Short Float	6.06%	Perf Quarter	-30.96%
Sales	0.80M	P/S	299.62	EPS this Y	-287.10%	Inst Trans	10.58%	Short Ratio	6.58	Perf Half Y	-31.58%
Book/sh	3.79	P/B	1.58	EPS next Y	-11.10%	ROA	-112.10%	Target Price	-	Perf Year	-43.40%
Cash/sh	5.77	P/C	1.04	EPS next 5Y	-	ROE	-292.30%	52W Range	6.01 - 14.44	Perf YTD	-46.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-66.40%	52W High	-58.45%	Beta	3.03
Dividend %	-	Quick Ratio	28.20	Sales past 5Y	21.40%	Gross Margin	-	52W Low	-0.17%	ATR	0.42
Employees	15	Current Ratio	28.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.38	Volatility	5.39% 5.91%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	58.40%	Profit Margin	-	Rel Volume	0.89	Prev Close	6.24
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	312.35K	Price	6.00
Recom	1.30	SMA20	-11.16%	SMA50	-22.72%	SMA200	-36.08%	Volume	279,104	Change	-3.85%

Jun-09-21

Resumed

Jefferies

Buy

$20

Dec-23-20

Initiated

Piper Sandler

Overweight

$22

Oct-14-20

Initiated

Ladenburg Thalmann

Buy

Jul-27-21 07:00AM	Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021 PR Newswire
Jul-13-21 11:11AM	Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy? Insider Monkey
Jun-29-21 07:00AM	Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021 PR Newswire
Jun-15-21 11:37AM	2 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
May-26-21 07:00AM	Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021 PR Newswire +5.65%
May-12-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results PR Newswire
May-03-21 07:00AM	Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer PR Newswire
Apr-06-21 07:00AM	Cogent Biosciences Announces Creation of Cogent Research Team PR Newswire
Mar-17-21 02:27AM	Do Institutions Own Cogent Biosciences, Inc. (NASDAQ:COGT) Shares? Simply Wall St.
Mar-16-21 07:00AM	Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results PR Newswire +6.72%
Feb-22-21 07:00AM	Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors PR Newswire -5.60%
Feb-18-21 07:00AM	Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 PR Newswire
Feb-11-21 07:00AM	Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021 PR Newswire
Dec-04-20 05:16PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares PR Newswire
Dec-01-20 11:08PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock PR Newswire +6.73%
Nov-30-20 04:01PM	Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock PR Newswire
07:00AM	Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer PR Newswire
Nov-20-20 07:00AM	Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference PR Newswire
Nov-18-20 09:00AM	Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020 PR Newswire
Nov-12-20 04:30PM	Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference PR Newswire
Nov-09-20 07:00AM	Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates PR Newswire
Nov-05-20 07:00AM	Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire -5.32%
Oct-26-20 07:00AM	Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer PR Newswire
Apr-01-20 01:42AM	Edited Transcript of COGT earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -6.36%
Nov-13-19 06:22PM	Edited Transcript of COGT earnings conference call or presentation 11-Nov-19 9:30pm GMT Thomson Reuters StreetEvents

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Green John L.	Chief Financial Officer	Apr 26	Sale	8.86	17,813	157,823	3,841	Apr 28 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience